Table 5.
The recent trend in the clinical trials for targeting PD-L1 for TNBC patients.
| No. | Intervention | Mechanism of Action | Phase | Study Start Date | The Status | Clinicaltrials.gov Identifier |
|---|---|---|---|---|---|---|
| 1 | Atezolizumab and Paclitaxel | PD-L1 blockade and disrupting mitosis | III | 25 Aug 2017 | Active, not recruiting | NCT03125902 |
| 2 | Atezolizumab and nab-Paclitaxel | PD-L1 blockade and disrupting mitosis | III | 17 Dec 2019 | Recruiting | NCT04148911 |
| 3 | Atezolizumab and nab-Paclitaxel | PD-L1 blockade and disrupting mitosis | III | 23 Jun 2015 | Active, not recruiting | NCT02425891 |
| 4 | Atezolizumab, radiation, and Talazoparib | PD-L1 blockade and inducing DNA damage | II | 1 Apr 2021 | Recruiting | NCT04690855 |
| 5 | Atezolizumab, Paclitaxel, Doxorubicin/Epirubicin, and Cyclophosphamide | PD-L1 blockade, disrupting mitosis, DNA synthesis inhibition, and protein synthesis inhibition | III | 2 Aug 2018 | Recruiting | NCT03498716 |
| 6 | Avelumab | PD-L1 blockade | III | Jun 2016 | Active, not recruiting | NCT02926196 |
| 7 | Atezolizumab | PD-L1 blockade | III | 19 Dec 2017 | Recruiting | NCT03281954 |
| 8 | Atezolizumab, Pegylated liposomal doxorubicin, and Cyclophosphamide | PD-L1 blockade, DNA synthesis inhibition, and protein synthesis inhibition | II | 1 Jun 2017 | Recruiting | NCT03164993 |
| 9 | Durvalumab and Olaparib | PD-L1 blockade and DNA repair inhibition | II | 4 Oct 2018 | Active, not recruiting | NCT03167619 |
| 10 | Avelumab and Palbociclib | PD-L1 blockade and inhibiting DNA replication | I | 11 Aug 2020 | Recruiting | NCT04360941 |
| 11 | Atezolizumab, Bevacizumab, Gemcitabine, and Carboplatin | PD-L1 blockade, inhibiting angiogenesis, DNA synthesis inhibition, and suppressing DNA synthesis | II | Feb 2021 | Not yet recruiting | NCT04739670 |
| 12 | Durvalumab and Carboplatin | PD-L1 blockade and DNA synthesis inhibition | II | 29 Aug 2017 | Active, not recruiting | NCT03206203 |
| 13 | Durvalumab, Oleclumab, Paclitaxel, and Carboplatin | PD-L1 blockade, CD73 blockade, disrupting mitosis, and DNA synthesis inhibition | I/II | 28 Dec 2018 | Recruiting | NCT03616886 |
| 14 | Atezolizumab and nab-Paclitaxel | PD-L1 blockade and disrupting mitosis | II | 4 Feb 2016 | Active, not recruiting | NCT02530489 |
| 15 | Durvalumab and CFI-400945 | PD-L1 blockade and PLK4 inhibition | II | 19 Dec 2019 | Recruiting | NCT04176848 |
| 16 | Durvalumab | PD-L1 blockade | I/II | Nov 2015 | Active, not recruiting | NCT02489448 |
| 17 | Atezolizumab and Capecitabine | PD-L1 blockade and inhibiting DNA synthesis | II | 15 Jan 2019 | Recruiting | NCT03756298 |
| 18 | Atezolizumab, Ipatasertib, and Paclitaxel | PD-L1 blockade, Akt inhibition and disrupting mitosis | III | 25 Nov 2019 | Active, not recruiting | NCT04177108 |
| 19 | Atezolizumab, Bevacizumab, and Paclitaxel | PD-L1 blockade, inhibiting angiogenesis and disrupting mitosis | II | 5 Oct 2020 | Recruiting | NCT04408118 |
| 20 | Atezolizumab, Gemcitabine, Capecitabine, and Carboplatin | PD-L1 blockade, DNA synthesis inhibition, inhibiting DNA synthesis and suppressing DNA synthesis | III | 11 Jan 2018 | Recruiting | NCT03371017 |